# Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Study · id `cardio:ct-nct02002221` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02002221](<https://clinicaltrials.gov/study/NCT02002221>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02002221

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

## Technical summary

Registry record NCT02002221. Randomized; triple masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-03-01.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 156 participants (enrolled count; ClinicalTrials.gov record NCT02002221, source copy `cardio:ctgov-nct02002221-2016-03-01`, retrieved 2026-10-26)
- Start date: 2013-12 (registry gives no type) (ClinicalTrials.gov record NCT02002221, source copy `cardio:ctgov-nct02002221-2016-03-01`, retrieved 2026-10-26)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02002221, source copy `cardio:ctgov-nct02002221-2016-03-01`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02002221, source copy `cardio:ctgov-nct02002221-2016-03-01`, retrieved 2026-10-26)
- Results first posted: 2016-03-01 (ClinicalTrials.gov record NCT02002221, source copy `cardio:ctgov-nct02002221-2016-03-01`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02002221, source copy `cardio:ctgov-nct02002221-2016-03-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02002221-2016-03-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): Vildagliptin (LAF237)
- Intervention (Drug): Placebo
- Intervention (Drug): Insulin
- Intervention (Drug): Metformin
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 4305ac8e19013e792990d7a5813bfedef3abc8ce59e95a6ad13abc30ee598daf
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
